The question arises from almost every client, “Why do we have to do daily rejected claims review?” The answer is that there is no better way “to take the temperature” of Part D compliance than rejected claim reviews. Everything that can and will occur happens at Point of Sale. At a minimum you can detect problems with the following:
- Part B vs Part D
- Concurrent DUR edits (non-approved by CMS) restricting medication access
- Inappropriate protected class drug rejects
- Short cycle dispensing
- Minimum packaging size
- NPI processing
Rejected claims analysis is a year-round activity, with special emphasis that will begin in January. Beneficiaries should be able to receive the Part D drugs they are entitled to, consistent with CMS guidance, from January 1st through December 31st of the plan year.
Processes can be designed to organize and streamline the review so that the most relevant and consequential rejects are included. With consistent and thorough reviews, the organization has a foundation for healthy Part D compliance.
Want to stay up to date on policy and regulation changes? The Insider is GHG’s exclusive intelligence briefing, providing in-depth analysis and expert summaries of the most critical legislative and political activities impacting and shaping your organization. Read our full press release >>
Stay connected to industry news and gain perspective on how to navigate the latest issues through GHG’s weekly newsletter. Subscribe >>Contact Us